1,3,5-triazine compounds (Progenics)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Name1,3,5-triazine compounds (Progenics)
Drug Alias Namehepatitis C viral entry inhibitors (Progenics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVirus uptake inhibitors
TargetsUpdating
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProgenics Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProgenics Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A